Helus Pharma (HELP) Q4 2026 earnings summary

Executive summary

• Clinical-stage pharmaceutical company focused on psychiatric and neurological therapies, with significant R&D and business development activities during the year.

• Completed major equity and warrant financings, repaid convertible debentures, and changed functional and presentation currency to USD.

• No impairment recognized on goodwill or intangible assets after annual testing.

Financial highlights

• Cash increased to $157.3M as of March 31, 2026, from $93.9M a year earlier.

• Net loss for the year was $148.0M, compared to $81.6M in the prior year.

• Total revenue not reported; expenses rose to $142.6M from $103.1M year-over-year.

• Shareholders’ equity increased to $231.8M from $165.0M year-over-year.

• Weighted average shares outstanding rose to 34.8M from 20.2M year-over-year.

Outlook and guidance

• Company expects to pay up to $86.7M for ongoing studies over the next 24 months, contingent on milestones and material availability.

• Additional milestone payments of up to $9.5M may be required under a license agreement, subject to achievement of development milestones.